Form 4: Neurogene CSO Sells Shares Under 10b5-1 Plan

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, sold a total of 6,797 shares of common stock on March 13, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Stuart Cobb, Chief Scientific Officer of Neurogene Inc. (NGNE), reported the sale of common stock.
• The transactions occurred on March 13, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2025.
• A total of 6,797 shares of common stock were sold across three separate transactions.
• The shares were sold at weighted average prices of $20.41, $21.34, and $22.08.
• Specifically, 3,991 shares were sold at a weighted average price of $20.41 (ranging from $19.94 to $20.93).
• Another 2,658 shares were sold at a weighted average price of $21.34 (ranging from $20.97 to $21.96).
• An additional 148 shares were sold at a weighted average price of $22.08 (ranging from $21.97 to $22.16).
• Following these transactions, Stuart Cobb beneficially owns 30,497 shares of common stock.
• Beneficial ownership includes 6,797 restricted stock units (RSUs) granted on March 13, 2025, vesting on March 13, 2027.
• Beneficial ownership also includes 7,200 RSUs granted on March 23, 2025, vesting annually in equal installments on March 23, 2026, March 23, 2027, and March 23, 2028.
• Additionally, beneficial ownership includes 16,500 RSUs granted on February 20, 2026, vesting annually in equal installments on February 20, 2027, February 20, 2028, and February 20, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. While insider selling can sometimes be perceived negatively, the transactions were executed under a pre-arranged 10b5-1 plan, indicating a planned diversification rather than a reaction to new, undisclosed negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially suggesting that the insider believes the stock is fully valued or overvalued.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a pre-arranged 10b5-1 plan, are a common practice for executives to manage personal finances, diversify their portfolios, and realize gains from equity compensation. In the biotechnology sector, such transactions are often viewed as routine financial planning rather than a direct signal about the company's immediate operational performance or future prospects, especially when the amounts are not exceptionally large relative to total holdings.

Stakeholder Impact

• Shareholders might interpret the sale differently, but the disclosure of a 10b5-1 plan helps mitigate concerns that the sale is based on new, non-public information, suggesting it's part of routine financial planning.

Next Steps

• Vesting of 6,797 restricted stock units on March 13, 2027.
• Annual vesting of 7,200 restricted stock units on March 23, 2026, March 23, 2027, and March 23, 2028.
• Annual vesting of 16,500 restricted stock units on February 20, 2027, February 20, 2028, and February 20, 2029.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings. This type of transaction typically does not reflect new material information about the company's operational performance or future prospects. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

Neurogene, NGNE, Stuart Cobb, insider trading, Form 4, stock sale, 10b5-1 plan, Chief Scientific Officer, restricted stock units